These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37755833)

  • 1. Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings: Two Randomized Clinical Trials.
    Sigmon SC; Peck KR; Batchelder SR; Badger GJ; Heil SH; Higgins ST
    JAMA Netw Open; 2023 Sep; 6(9):e2331910. PubMed ID: 37755833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
    Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
    Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
    Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of an interactive voice response system for daily monitoring of illicit opioid use during buprenorphine treatment.
    Parker MA; Ochalek TA; Rose GL; Badger GJ; Sigmon SC
    Psychol Addict Behav; 2018 Dec; 32(8):956-960. PubMed ID: 30359047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
    D'Onofrio G; O'Connor PG; Pantalon MV; Chawarski MC; Busch SH; Owens PH; Bernstein SL; Fiellin DA
    JAMA; 2015 Apr; 313(16):1636-44. PubMed ID: 25919527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study.
    Ochalek TA; Heil SH; Higgins ST; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2018 Sep; 190():224-228. PubMed ID: 30056321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.
    Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E
    Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial.
    Stopka TJ; Babineau DC; Gibson EB; Knott CE; Cheng DM; Villani J; Wai JM; Blevins D; David JL; Goddard-Eckrich DA; Lofwall MR; Massatti R; DeFiore-Hyrmer J; Lyons MS; Fanucchi LC; Harris DR; Talbert J; Hammerslag L; Oller D; Balise RR; Feaster DJ; Soares W; Zarkin GA; Glasgow L; Oga E; McCarthy J; D'Costa L; Chahine R; Gomori S; Dalvi N; Shrestha S; Garner C; Shadwick A; Salsberry P; Konstan MW; Freisthler B; Winhusen J; El-Bassel N; Samet JH; Walsh SL
    JAMA Netw Open; 2024 Feb; 7(2):e240132. PubMed ID: 38386322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
    Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
    JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
    Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
    JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial.
    Ware OD; Sweeney MM; Cunningham C; Umbricht A; Stitzer M; Dunn KE
    JAMA Netw Open; 2023 Mar; 6(3):e232278. PubMed ID: 36920397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.